Apollo Ingredients Faces Scrutiny: ₹3 Cr Rights Issue Funds Diverted for Lease

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorAditi Singh|Published at:
Apollo Ingredients Faces Scrutiny: ₹3 Cr Rights Issue Funds Diverted for Lease
Overview

Apollo Ingredients Limited has disclosed a significant deviation in the utilisation of its Rights Issue proceeds. The company raised ₹5 crore but used ₹3 crore for lease payments to a related party, deviating from the original stated objective of working capital. While shareholder approval for the specific lease transaction was later obtained, a monitoring agency noted the deviation, raising governance concerns.

Apollo Ingredients Faces Heat Over ₹3 Cr Rights Issue Fund Diversion

Apollo Ingredients raised ₹5 crore via rights issue, with ₹3 crore now noted as deviated for lease payments to a related party.
Reader Takeaway: Shareholder nod for lease follows fund deviation; related party transaction faces scrutiny.

What just happened (today’s filing)

Apollo Ingredients Limited has filed a statement of deviation regarding the utilisation of funds raised through its recent Rights Issue. The company had raised ₹5.00 crore (₹500.00 lakh) on August 12, 2025.

However, a substantial portion, ₹3.00 crore (₹300.00 lakh), was used for lease payments on a factory leased from a related party, Apollo Ingredients India Private Limited. This deviates from the original primary objective which was working capital, like raw material procurement.

The company's monitoring agency, Infomerics Valuation and Rating Limited, noted this deviation. While specific shareholder approval for the 10-year factory lease transaction itself was obtained on September 27, 2025, the monitoring agency highlighted a lack of specific shareholder approval for altering the stated use of proceeds.

Why this matters

Deviation from stated objectives in the utilisation of funds raised via a rights issue is a serious governance concern. It suggests a potential misalignment between management's actions and investor disclosures. Regulators and investors scrutinise such events closely, as they can impact transparency and the intended purpose of capital raising.

The backstory (grounded)

Apollo Ingredients, formerly known as Indsoya Limited, has undergone a business evolution. Originally involved in oils and oil seeds, it has shifted towards healthcare solutions, including manufacturing and trading of Ayurvedic, homeopathic, and allopathic medicines, as well as medical facility planning.

The ₹5 crore rights issue was conducted from July 16 to July 29, 2025, with a record date of July 7, 2025. The initial allocation proposed ₹3.65 crore for working capital.

Separately, the company had secured shareholder approval at its 45th Annual General Meeting on September 27, 2025, for a 10-year factory lease with Apollo Ingredients India Private Limited, not exceeding ₹3 crore.

Earlier in January 2026, Apollo Ingredients Limited had filed an appeal with the Securities Appellate Tribunal (SAT) against BSE, challenging regulatory actions including fines and demat account freezes linked to alleged SEBI LODR violations.

What changes now

  • Increased scrutiny from regulatory bodies like SEBI and stock exchanges.
  • Potential for greater oversight on future fund utilisation.
  • Heightened investor awareness regarding related party transactions and compliance.
  • Need for enhanced transparency in disclosing changes to use of proceeds from capital-raising activities.

Risks to watch

  • Fund Utilisation Deviation: Using ₹3 crore from rights issue proceeds for lease payments instead of the declared working capital purpose is a significant deviation.
  • Related Party Transaction Governance: Leasing a factory from Apollo Ingredients India Private Limited, a related entity, for this purpose raises governance questions, especially concerning the process of fund allocation.
  • Monitoring Agency Observations: The monitoring agency has flagged the deviation and the lack of specific shareholder approval for altering the stated use of funds, indicating potential non-compliance with disclosure norms.
  • Past Regulatory Issues: The company's recent appeal to the SAT against BSE fines and demat account freezes for alleged SEBI LODR violations suggests a history of regulatory compliance challenges.

Peer comparison

While direct peer comparisons for fund utilisation deviations are difficult, other companies in the food ingredients and healthcare sectors operate under similar disclosure norms.

  • Ruchi Soya Industries (Patanjali Foods), involved in edible oils and food products, is subject to regular disclosures on its business operations and fund management.
  • Nestle India, a major player in packaged foods, faces high investor expectations for transparency in its financial and operational reporting.
  • Vidhi Specialty Food Ingredients Ltd operates in a segment where adherence to product quality and financial integrity is paramount for market trust.

Context metrics (time-bound)

  • Apollo Ingredients raised ₹5.00 crore via Rights Issue in July 2025.
  • ₹3.00 crore of these proceeds were utilised for advance lease payments by the quarter ended December 31, 2025.
  • Shareholder approval for the specific lease transaction was obtained on September 27, 2025.

What to track next

  • Further clarifications from the company regarding the rationale for fund deviation and steps taken to rectify compliance gaps.
  • Any potential actions or notices from SEBI or stock exchanges regarding the fund utilisation deviation and governance concerns.
  • Future disclosures on related party transactions and adherence to capital allocation plans.
  • The outcome of the ongoing appeal filed with the Securities Appellate Tribunal (SAT) concerning past regulatory issues.
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.